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ABSTRACT
Objective: This study aimed to evaluate the length of stay (LOS), costs,
and treatment consistency among patients hospitalized with community-
acquired pneumonia (CAP) initially treated with intravenous (IV) moxi-
ﬂoxacin 400 mg or IV levoﬂoxacin 750 mg.
Methods: Adults with CAP receiving IV moxiﬂoxacin or IV levoﬂoxacin
for 3 days were identiﬁed in the Premier Perspective comparative data-
base. Primary outcomes were LOS and costs. Secondary outcomes
included treatment consistency, which was deﬁned as 1) no additional IV
moxiﬂoxacin or levoﬂoxacin after 1 day off study drug; 2) no switch to
another IV antibiotic; and 3) no addition of another IV antibiotic.
Results: A total of 7720 patients met inclusion criteria (6040 receiving
moxiﬂoxacin; 1680 receiving levoﬂoxacin). Propensity matching created
two cohorts (1300 patients each) well matched for demographic, clinical,
hospital, and payor characteristics. Before the patients were matched,
mean LOS (5.87 vs. 5.46 days; P = 0.0004) and total costs per patient
($7302 vs. $6362; P < 0.0001) were signiﬁcantly greater with moxiﬂoxa-
cin. After the patients were matched, mean LOS (5.63 vs. 5.51 days;
P = 0.462) and total costs ($6624 vs. $6473; P = 0.476) were comparable
in both cohorts. Treatment consistency was higher for moxiﬂoxacin before
(81.0% vs. 78.9%; P = 0.048) and after matching (82.8% vs. 78.0%;
P = 0.002).
Conclusions: In-hospital treatment of CAP with IV moxiﬂoxacin 400 mg
or IV levoﬂoxacin 750 mg was associated with similar hospital LOS and
costs in propensity-matched cohorts.
Keywords: community-acquired pneumonia, cost, hospital, length of stay,
levoﬂoxacin, moxiﬂoxacin, treatment outcomes.
Introduction
Community-acquired pneumonia (CAP) occurs in an estimated 5
to 6 million persons annually in the United States and results in
approximately 60,000 deaths [1,2]. Each year, CAP is respon-
sible for an estimated 10 million physician visits and more than
1 million hospitalizations [3,4]. A cost-of-illness study found that
the total direct cost for treating CAP was $8.4 billion (in 1995
dollars), of which $4.8 billion was for patients 65 years of age
[1]. Eighty-nine percent of the total cost, or $7.5 billion, was for
inpatient care. According to the 2005 Nationwide Inpatient
Sample, the average hospital length of stay (LOS) for CAP was
5.52 days, and in-hospital mortality was 4% [5].
The Infectious Diseases Society of America (IDSA) and the
American Thoracic Society (ATS) recently issued consensus guide-
lines for the management of adults with CAP to identify patients
who should be hospitalized, as well as antibiotics for empiric use
before a causative pathogen has been isolated [6]. Several studies
have shown that the implementation of the IDSA/ATS guidelines
leads to improved patient care with concomitant reductions in
hospital LOS, costs, and readmissions [7–9]. Other studies have
demonstrated that such reductions in LOS produce substantial
cost savings without adversely affecting mortality, readmission
rates, or the time needed to return to normal activities [10,11].
The decision to hospitalize a patient is based on the severity
of illness and the clinicians’ determination of a range of factors,
including the likelihood that the patient will reliably take oral
medications [6]. The IDSA/ATS guidelines recommend hospital-
ization or, where available and appropriate, intensive, in-home
health-care services, for patients with confusion, urea, respira-
tory rate, blood pressure, and age 65 years scores 2. Empiric
antibiotic therapy in hospitalized patients should consist of a
respiratory ﬂuoroquinolone (e.g., moxiﬂoxacin or levoﬂoxacin)
or alternatively, a beta-lactam (e.g., cefotaxime, ceftriaxone,
ampicillin, or for selected patients, ertapenem) plus macrolide
regimen [6]. When patients are admitted directly to an intensive
care unit (ICU), empiric therapy should consist of a beta-lactam
plus either a respiratory ﬂuoroquinolone or azithromycin.
The safety and efﬁcacy of respiratory ﬂuoroquinolones in
hospitalized patients with CAP have been demonstrated in
numerous studies [12–15]. Comparisons to beta-lactam–
macrolide regimens or nonstandardized regimens suggest that
ﬂuoroquinolones lead to earlier hospital discharge, which in
some studies has led to cost savings [16–18]. In the Community-
Acquired Pneumonia Recovery in the Elderly study, a pro-
spective, randomized, double-blind trial, treatment with
moxiﬂoxacin 400 mg daily was associated with signiﬁcantly
faster clinical recovery than treatment with levoﬂoxacin 500 mg
daily in hospitalized elderly patients with CAP, although the
clinical cure rates did not differ signiﬁcantly when assessed 5 to
21 days after completion of treatment [15]. Nevertheless, a
recent retrospective database analysis of hospitalized patients
with CAP suggested that initial treatment with intravenous (IV)
levoﬂoxacin 750 mg reduced hospital LOS by 0.5 day when
compared with initial treatment with IV moxiﬂoxacin 400 mg
[19]. Comparisons between levoﬂoxacin and moxiﬂoxacin in
that study may have been limited by methodological issues. To
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address these issues, we also conducted a retrospective database
analysis to evaluate LOS and costs, as well as treatment consis-
tency, among patients with CAP treated with IV moxiﬂoxacin
400 mg or IV levoﬂoxacin 750 mg daily. Our objective was to
compare treatment costs and outcomes (LOS and treatment con-
sistency) with moxiﬂoxacin and levoﬂoxacin from the payor’s




Data from the Premier Perspective comparative database (PCD;
Charlotte, NC) from April 2003 to March 2006 were analyzed.
The PCD contains inpatient data from more than 500 acute-care
facilities in the United States that represent all geographic areas,
urban and rural facilities, teaching and nonteaching hospitals,
and a broad range of hospital sizes [20]. The database includes
standard hospital admission and discharge information as well as
date-stamped logs of all billed items for procedures, medications,
and laboratory, diagnostic, and therapeutic services at the indi-
vidual patient level. Hospitals submit data to the PCD on a
monthly or quarterly basis. The data undergo extensive quality
assurance and data validation checks, and the cost information is
reconciled with the hospitals’ ﬁnancial statements before the data
are made available for research.
Eligibility Criteria
Patients 18 years of age with a principal diagnosis of CAP
[International Classiﬁcation of Diseases, Ninth Revision (ICD-9)
codes: 481, 482.xx, 483.xx, 485, 486, and 487.x] who were
treated for 3 days with either IV moxiﬂoxacin 400 mg or IV
levoﬂoxacin 750 mg beginning on the date of hospital admission
or on the following day were identiﬁed [21,22]. Patients who
were admitted from or discharged to another acute-care hospital,
nursing home, or other long-term care facility and those dis-
charged from the hospital in the previous month were excluded
to ensure that the pneumonia episode was community acquired
and not nosocomial and that only complete episodes of inpatient
care were examined. Patients were also excluded if they were
discharged with surgical diagnosis-related groups (DRGs) (i.e.,
only patients with DRGs 79, 80, 89, 90, 475, and 565 were
eligible), received a ﬁrst IV dose with an antibiotic other than
moxiﬂoxacin or levoﬂoxacin, switched antibiotic therapy during
the ﬁrst 3 days of hospitalization, had a hospital LOS of <3 days,
or had a discharge status of death.
Patient Population
The patient population was characterized by a series of demo-
graphic and clinical variables, payor and provider variables,
and medication-related variables. The demographic variables
included patient age, sex, race, and year of admission. Clinical
variables included the type of pneumonia based on the three-digit
level principal discharge ICD-9 code, and comorbidities and
CAP complications derived from the secondary diagnosis ICD-9
codes in the admission record. The CAP complications provide a
measure of initial CAP severity and include sepsis, respiratory
failure, pleural effusion and empyema, abscess, renal failure, and
congestive heart failure. In addition, the severity of illness and
risk of mortality were assessed by using the All Patient Reﬁned
DRG (APR-DRG). Other severity-related clinical variables that
were captured included intubation at any time during an admis-
sion, respiratory therapy within the ﬁrst 24 hours after admis-
sion, and total length of stay in the ICU. Payor data were
grouped into the following categories: Medicare, Medicaid,
private insurance, uninsured, other, and unknown. Provider data
were characterized by region (Northeast, Midwest, South, and
West), location (urban or rural), teaching hospital status, number
of beds, admission from the emergency department, and specialty
of the admitting and attending physicians. Medication-related
variables included the number of doses of study drug that were
administered during the hospital stay and the average daily dose
of the study drug.
Outcome Variables
The primary outcome variables were total costs (in US dollars)
per hospital admission with CAP and LOS per admission with
CAP. The LOS represented the total number of days in the
hospital, from the day of admission to the day of discharge.
Because this study covered a 3-year period, total costs for the
index hospitalization were calculated according to the discharge
month and then standardized into March 2006 dollars by using
the corresponding Consumer Price Index Medical Care for that
month. The costs for the components of care—a secondary
outcome variable—were identiﬁed by using UB-92 revenue codes
and standardized by using the Consumer Price Index Medical
Care. These costs included room and board (UB-92 revenue
codes 110–219), pharmacy (codes 25x and 63x), IV therapy
supplies (code 26x), respiratory therapy (code 41x), and all other
costs (identiﬁed by other revenue codes). Other secondary
outcome variables included treatment consistency. Treatment
consistency was achieved if the patients met all of the following
three criteria: 1) they did not require an additional dose of IV
moxiﬂoxacin or levoﬂoxacin during the same hospital stay after
being off the study drug for at least 1 day (retreatment); 2) they
did not switch to another IV antibiotic (switch); and 3) they did
not require the addition of another IV antibiotic (add-on).
Statistical Analyses
Statistical analysis was performed by using Statistical Analysis
Software (SAS; SAS Institute Inc., Cary, NC). The conditional
logistic regression analysis was conducted by using SAS 9.1, and
the rest of the analyses were conducted by using SAS 8.2. Base-
line demographic and other information were presented because
either counts (%) for categorical data or mean (SD) for con-
tinuous data. Descriptive proﬁles were calculated for all variables
before and after propensity score matching. Categorical variables
were evaluated by using chi-square tests, and continuous vari-
ables were analyzed by using nonparametric rank-sum tests.
Outcomes were compared in three different manners: pre-
matched unadjusted comparison, postmatched unadjusted com-
parison, and postmatched comparison adjusted for factors
thought to inﬂuence outcome. Because patients were not ran-
domly allocated to study treatment, propensity score matching
was used to develop comparable cohorts of patients treated with
IV moxiﬂoxacin and IV levoﬂoxacin having similar distributions
of patient characteristics [23]. The probability that a patient
received moxiﬂoxacin as the index drug was modeled by using
demographics, hospital characteristics, and baseline clinical char-
acteristics. Variables that affect treatment choice and outcomes
were included in the matching process, including age, sex, race,
type of pneumonia, severity measures, comorbidities, CAP com-
plications, type of payor, hospital teaching status, hospital size,
region, location, admitting and attending physician specialty,
emergency department admission, and year of admission. The
logistic regression model was constructed in a stepwise manner
to predict the probability of moxiﬂoxacin use by each patient.
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After the logistic regression model was estimated, individuals
in the moxiﬂoxacin cohort were matched one to one with the
pool of levoﬂoxacin users who had similar propensity scores
using a greedy match [24]. Sampling without replacement was
used when creating the propensity-matched samples. The quality
of the match was examined by using descriptive statistics tests,
including chi-square and rank-sum tests. A multivariate analysis
was performed on the matched samples to examine the marginal
effects of speciﬁc factors on outcomes of interest. Generalized
linear models were used when costs and cost components were
the outcome (Gamma distribution), count data models (Poisson
regression) were used for LOS, and a conditional logistic model
stratiﬁed on the match was used for treatment consistency. Inde-
pendent variables included in these models were demographic
and clinical characteristics, payor, hospital characteristics, phy-
sician specialty, emergency department admission, year of admis-
sion, and treatment with moxiﬂoxacin or levoﬂoxacin. For the
multivariate analysis related to LOS and the GLM related to total
costs, P-values and Wald 95% conﬁdence intervals (CI) are pre-
sented from the models without any adjustments.
Results
Patient Cohorts
A total of 34,287 patients with CAP who were discharged after
receiving either moxiﬂoxacin or levoﬂoxacin during the 3-year
study period were identiﬁed in the PCD. Of these, 6040 (25.4%)
of 23,746 patients who received moxiﬂoxacin and 1680 (15.9%)
of 10,541 patients who received levoﬂoxacin met eligibility cri-
teria and were included in this analysis.
The unmatched moxiﬂoxacin and levoﬂoxacin cohorts dif-
fered signiﬁcantly in terms of a variety of demographic, clinical,
and hospital characteristics. Patients who received moxiﬂoxacin
tended to be older [mean (SD) age, 70.5 (15.2) vs. 68.4 (15.7)
years; P < 0.0001], were more likely to have comorbid cardio-
vascular disease, and were less likely to have chronic obstructive
pulmonary disorder or asthma (all P < 0.0001) (Table 1). The
severity of illness estimated by APR-DRG severity and risk of
mortality were generally higher in the moxiﬂoxacin group (both
P < 0.0001), whereas CAP complications were generally evenly
balanced between groups, apart from congestive heart failure,
which was more common in the moxiﬂoxacin group (45.7% vs.
40.4%; P = 0.0001), and sepsis, which was more common in the
levoﬂoxacin group (2.9% vs. 5.7%; P < 0.0001). In terms of
hospital characteristics, patients in the moxiﬂoxacin group were
more likely to be treated at a teaching hospital (49.1% vs.
38.5%; P < 0.0001), in an urban location (93.4% vs. 77.9%;
P < 0.0001), and/or at a larger facility [mean (SD) number of
beds = 465 (226) vs. 379 (214); P < 0.0001], and to be admitted
from the emergency department (84.7% vs. 76.3%; P < 0.0001)
(Table 2). The distribution by hospital region, year of admission,
and admitting physician specialty also differed signiﬁcantly
between groups (all P < 0.0001).
Propensity matching produced a total sample of 2600
patients, equally divided between the moxiﬂoxacin and levof-
loxacin cohorts. After matching, there were no statistically sig-
niﬁcant differences between the two cohorts in terms of
demographic, clinical, hospital, or payor characteristics (Tables 1
and 2). For the two combined cohorts, the mean age was 69
years; the majority were female (58%) and/or had comorbid
asthma (76%) or chronic obstructive pulmonary disorder (63%).
Most patients had at least one CAP complication (85%), most
commonly respiratory failure (66%), and slightly more than half
(55%) had moderate APR-DRG severity. Less than 1% of
Table 1 Demographic and clinical characteristics of the moxiﬂoxacin and levoﬂoxacin cohorts before and after matching
Characteristic








(N = 1300) P-value
Sex, no. (%)
Male 2442 (40.4) 686 (40.8) 0.766 553 (42.5) 536 (41.2) 0.499
Female 3598 (59.6) 994 (59.2) 747 (57.5) 764 (58.8)
Age, mean (SD), year 70.5 (15.2) 68.4 (15.7) <0.0001 69.2 (15.2) 69.1 (15.6) 0.986
Comorbid conditions, no. (%)
Cancer 417 (6.9) 127 (7.6) 0.353 100 (7.7) 92 (7.1) 0.549
Diabetes 1941 (32.1) 510 (30.4) 0.166 399 (30.7) 403 (31.0) 0.865
COPD 3239 (53.6) 1061 (63.2) <0.0001 812 (62.5) 814 (62.6) 0.935
Asthma 3769 (62.4) 1320 (78.6) <0.0001 991 (76.2) 989 (76.1) 0.927
Cardiovascular disease 1898 (31.4) 431 (25.7) <0.0001 353 (27.2) 351 (27.0) 0.930
Secondary diagnoses, mean (SD), no. 7.63 (3.76) 7.38 (3.57) 0.072 7.72 (3.96) 7.44 (3.44) 0.369
Any CAP complication, no. (%) 5187 (85.9) 1406 (83.7) 0.025 1105 (85.0) 1099 (84.5) 0.743
Sepsis 177 (2.9) 96 (5.7) <0.0001 59 (4.5) 62 (4.8) 0.780
Respiratory failure 3903 (64.6) 1088 (64.8) 0.914 874 (67.2) 852 (65.5) 0.361
Pleural effusion/empyema 319 (5.3) 95 (5.7) 0.548 65 (5.0) 79 (6.1) 0.230
Abscess 16 (0.3) 8 (0.5) 0.169 4 (0.3) 5 (0.4) 0.738
Renal failure 1548 (25.6) 427 (25.4) 0.860 361 (27.8) 364 (28.0) 0.896
Congestive heart failure 2758 (45.7) 678 (40.4) 0.0001 535 (41.2) 532 (40.9) 0.905
APR-DRG severity, no. (%)
Minor 485 (8.0) 171 (10.2) <0.0001 106 (8.2) 124 (9.5) 0.270
Moderate 3154 (52.2) 934 (55.6) 701 (53.9) 726 (55.8)
Major 2170 (35.9) 532 (31.7) 454 (34.9) 417 (32.1)
Extreme 231 (3.8) 43 (2.6) 39 (3.0) 33 (2.5)
APR-DRG mortality risk, no. (%)
Minor 1784 (29.5) 620 (36.9) <0.0001 452 (34.8) 455 (35.0) 0.977
Moderate 3312 (54.8) 854 (50.8) 678 (52.2) 678 (52.2)
Major 822 (13.6) 179 (10.7) 153 (11.8) 148 (11.4)
Extreme 122 (2.0) 27 (1.6) 17 (1.3) 19 (1.5)
Patients intubated, no. (%) 59 (1.0) 8 (0.5) 0.050 6 (0.5) 8 (0.6) 0.592
Patients receiving respiratory therapy, no. (%) 5130 (84.9) 1528 (91.0) <0.0001 1166 (89.7) 1168 (89.8) 0.897
APR-DRG,All Patient Reﬁned Diagnostic-Related Groups;CAP, community-acquired pneumonia;COPD,chronic obstructive pulmonary disorder.P-values are the result of bivariate comparisons.
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patients were intubated. Most patients were treated at an urban
hospital (85%), had Medicare coverage (69%), were admitted in
the year 2005 (52%), and/or were admitted after presentation to
the emergency department (79%).
Outcomes
Before propensity matching, the mean (SD) LOS was signiﬁcantly
longer (0.41 day) in the moxiﬂoxacin than in the levoﬂoxacin
cohort [5.87 (4.10) vs. 5.46 (3.45) days, respectively; P =
0.0004] (Fig. 1). Nevertheless, after propensity score matching,
there was no signiﬁcant difference in LOS between the moxi-
ﬂoxacin and levoﬂoxacin groups [5.63 (3.50) vs. 5.51 (3.52)
days; P = 0.462]. Total hospital costs showed a similar proﬁle,
with moxiﬂoxacin versus levoﬂoxacin having higher average
total costs in the unmatched population [$7302 ($10,754) vs.
$6362 ($4654), respectively; P < 0.0001], but no signiﬁcant dif-
ferences in the propensity-matched cohorts [$6624 ($5576) vs.
$6473  ($4782); P = 0.476] (Fig. 2).
Similarly, when individual cost components were evaluated,
higher room and board charges (P < 0.0001) and pharmacy
costs (P = 0.0003) were found in the moxiﬂoxacin group than
in the levoﬂoxacin group before matching. After propensity
matching, room and board charges (P = 0.239) and pharmacy
costs (P = 0.905) did not differ signiﬁcantly between the moxi-
ﬂoxacin and levoﬂoxacin cohorts (Table 3). The numeric differ-
ence between the two matched cohorts was $103 for room and
board costs and $33 for pharmacy costs. The cost of IV
Table 2 Payor and hospital characteristics of the moxiﬂoxacin and levoﬂoxacin cohorts before and after matching
Characteristic








(N = 1300) P-value
Payor type, no. (%)
Medicare 4152 (68.7) 1122 (66.8) <0.0001 894 (68.8) 896 (68.9) 0.979
Medicaid 299 (5.0) 114 (6.8) 76 (5.8) 81 (6.2)
Private insurance 1296 (21.5) 295 (17.6) 241 (18.5) 233 (17.9)
Uninsured 184 (3.0) 81 (4.8) 48 (3.7) 51 (3.9)
Other 109 (1.8) 68 (4.0) 41 (3.2) 39 (3.0)
Hospital region, no. (%)
Northeast 1572 (26.0) 196 (11.7) <0.0001 188 (14.5) 196 (15.1) 0.585
Midwest 1301 (21.5) 415 (24.7) 332 (25.5) 343 (26.4)
South 2817 (46.6) 868 (51.7) 655 (50.4) 622 (47.8)
West 350 (5.8) 201 (12.0) 125 (9.6) 139 (10.7)
Population density, no. (%)
Rural 399 (6.6) 371 (22.1) <0.0001 200 (15.4) 187 (14.4) 0.474
Urban 5641 (93.4) 1309 (77.9) 1100 (84.6) 1113 (85.6)
Teaching hospital, no. (%) 2963 (49.1) 646 (38.5) <0.0001 561 (43.2) 574 (44.2) 0.607
Hospital size, mean (SD) beds, no. 465.1 (226.4) 378.6 (213.9) <0.0001 389.0 (69.2) 390.5 (208.9) 0.637
Year of admission, no. (%)
2003 1119 (18.5) 16 (1.0) <0.0001 19 (1.5) 16 (1.2) 0.559
2004 1988 (32.9) 201 (12.0) 217 (16.7) 193 (14.8)
2005 2267 (37.5) 861 (51.3) 681 (52.4) 704 (54.2)
2006 666 (11.0) 602 (35.8) 383 (29.5) 387 (29.8)
Admission from emergency department, no. (%) 5117 (84.7) 1282 (76.3) <0.0001 1036 (79.7) 1024 (78.8) 0.562
Admitting physician specialty, no. (%)
Hospitalist 29 (0.5) 122 (7.3) <0.0001 29 (2.2) 14 (1.1) 0.207
Infectious disease 10 (0.2) 1 (0.1) 2 (0.2) 1 (0.1)
Primary care 4360 (72.2) 1238 (73.7) 1012 (77.8) 1015 (78.1)
Pulmonologist 299 (5.0) 114 (6.8) 89 (6.8) 93 (7.2)
Other 1342 (22.2) 205 (12.2) 168 (12.9) 177 (13.6)






























 (N=1,300)               (N=1,300)
P=0.462
After matching
Figure 1 Mean length of stay (standard deviation)
in moxiﬂoxacin and levoﬂoxacin cohorts before
and after matching.P-values are the result of bivari-
ate comparisons.
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therapy supplies was higher in the levoﬂoxacin group than in
the moxiﬂoxacin group both before (P < 0.0001) and after
(P = 0.0006) propensity matching; the differences between
treatment cohorts were $10 and $25, respectively. Respiratory
therapy costs and other costs did not differ between groups in
the prematched cohorts, whereas after matching, respiratory
therapy costs were $112 higher in the moxiﬂoxacin group
(P < 0.0001), and other costs were $71 higher in the levoﬂoxa-
cin group (P = 0.0043).
Moxiﬂoxacin was associated with a signiﬁcantly higher treat-
ment consistency than levoﬂoxacin before propensity matching
(81.0% vs. 78.9%, respectively; P = 0.0481) as well as after
matching (82.8% vs. 78.0%; P = 0.0018) (Fig. 3). These ﬁndings
reﬂected differences in retreatment rates (deﬁned as requiring an
additional dose of IV moxiﬂoxacin or levoﬂoxacin during the
same hospital stay after being off the study drug for at least 1
day), which were higher in the levoﬂoxacin group before pro-
pensity matching (13.6% vs. 11.9%, respectively; P = 0.060) and
signiﬁcantly higher in the levoﬂoxacin group after matching
(14.1% vs. 9.2%; P < 0.0001). Frequencies of regimen changes
from one study drug to another or to add-on therapy did not
differ between the moxiﬂoxacin and levoﬂoxacin cohorts before
or after propensity matching.
Factors Inﬂuencing Outcomes
Tables 4 and 5 present factors that signiﬁcantly affected LOS
(Table 4) and total costs (Table 5). In the multivariate analysis,
the choice of index drug (moxiﬂoxacin vs. levoﬂoxacin) was not
signiﬁcant in the estimation of the LOS (Table 4; 95% CI for
index drug regression coefﬁcient = -0.027 to 0.039) or the total
costs (Table 5; 9% CI for index drug regression coefﬁ-
cient = -0.048 to 0.025). On the other hand, a number of other
demographic, clinical, and hospital factors were signiﬁcant
predictors of one or both of these outcomes, resulting in models
with some predictive power; adjusted R2 = 0.33 and adjusted
R2 = 0.24 for the multivariate model for total costs and LOS,
respectively.
Clinical factors that were signiﬁcantly associated with LOS
included the need for intubation, the presence of an abscess, an
ICD-9 code for other bacterial pneumonia, the presence of
pleural effusion or empyema, the presence of congestive heart
failure, and the number of secondary diagnoses at admission (all
P < 0.0001) as well as APR-DRG severity (P = 0.0001). Female
sex (P < 0.0001) and advanced age (P = 0.001) were the only
demographic factors that emerged as signiﬁcant predictors of
LOS, whereas Medicare insurance (P = 0.0029) and other forms
of insurance (i.e., not Medicare, Medicaid, or private insurance)
(P = 0.0009) were signiﬁcantly associated with shorter mean
LOS. Hospital factors signiﬁcantly associated with longer LOS
included nonteaching facility, Northeast region, and admission in
2004 or 2005.
In general, the foregoing factors were also signiﬁcantly asso-
ciated with total hospital costs (Table 5). The proportion of
the LOS spent in the ICU strongly inﬂuenced total costs
(P < 0.0001), as did the need for intubation (P < 0.0001). Several
hospital characteristics, including nonteaching status, Northeast
region, rural location, admission in 2004, and admission from
Figure 2 Total costs (standard deviation) in
moxiﬂoxacin and levoﬂoxacin cohorts before and
after matching. P-values are the result of bivariate
comparisons.
Table 3 Medical costs and length of stay of moxiﬂoxacin and levoﬂoxacin cohorts before and after matching
Outcome








(N = 1300) P-value
Mean (SD) cost per patient, US$
Total cost 7,302 (10,754) 6,362 (4,654) <0.0001 6,624 (5,576) 6,473 (4,782) 0.476
Room and board 4,108 (8,709) 3,326 (2,753) <0.0001 3,536 (3,081) 3,433 (2,849) 0.239
Pharmacy 624 (951) 589 (743) 0.0003 620 (817) 587 (791) 0.905
IV therapy supplies 194 (251) 204 (265) <0.0001 177 (211) 202 (284) 0.0006
Respiratory therapy 467 (792) 387 (646) 0.992 496 (853) 384 (700) <0.0001
Other 1,099 (3,922) 1,855 (1,596) 0.293 1,796 (1,808) 1,867 (1,610) 0.0043
Mean (SD) length of stay, d 5.87 (4.10) 5.46 (3.45) 0.0004 5.63 (3.50) 5.51 (3.52) 0.462
IV, intravenous. P-values are the result of bivariate comparisons.
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the emergency department, were signiﬁcantly predictive of total
costs (Table 5), but payor factors were not (data not shown).
Patients treated with moxiﬂoxacin were more likely to
achieve treatment consistency than those receiving levoﬂoxacin
[odds ratio (OR) = 1.40; P = 0.0048, global null hypothesis like-
lihood ratio P < 0.001]. Regardless of whether patients received
moxiﬂoxacin or levoﬂoxacin, they were less likely to achieve
treatment consistency if they had a higher number of secondary
diagnoses (OR = 0.914; P = 0.001) or a higher APR-DRG risk of
mortality (OR = 0.638; P = 0.015). No other demographic, clini-
cal, hospital, or payor characteristic was a signiﬁcant predictor of
treatment consistency.
Discussion
Results of the present study indicate that neither clinical nor
formulary decisions concerning levoﬂoxacin or moxiﬂoxacin for
CAP can be made strictly on the basis of different costs of care,
including LOS. This retrospective database analysis demon-
strated that daily IV treatment with moxiﬂoxacin 400 mg or
levoﬂoxacin 750 mg was associated with similar hospital LOS
and total costs in a matched cohort of patients with CAP. Before
propensity matching, the moxiﬂoxacin and levoﬂoxacin cohorts
differed considerably in demographic and clinical characteristics
known to inﬂuence LOS and costs, such as advanced age, illness
severity, and mortality risk, as well as in various hospital- and
payor-based characteristics that can also impact these outcomes.
Because patients were not randomly allocated to moxiﬂoxacin or
levoﬂoxacin treatment, estimation of treatment effects on LOS
and costs may be biased by such imbalances between treatment
groups. Accordingly, comparisons of outcomes between cohorts
receiving one of the two ﬂuoroquinolones before successful pro-
pensity matching are not a reliable means of concluding that LOS
or total costs differ between moxiﬂoxacin and levoﬂoxacin.
Propensity score matching was developed to reduce bias
between two imbalanced study groups. Heckman and colleagues
Figure 3 Treatment consistency in moxiﬂo-
xacin and levoﬂoxacin cohorts before and after
matching. P-values are the result of bivariate
comparisons.
Table 4 Results of multivariate analysis of variables associated with length of stay (LOS)
Variable Estimated coefﬁcients Wald 95% CI P-value
Moxiﬂoxacin 0.0057 -0.027 to 0.039 0.734
Demographic factors
Age 0.0027 0.001–0.004 0.001
Female 0.0707 0.036–0.105 <0.0001
Clinical factors
ICD-9 code 482 (other bacterial pneumonia) 0.2588 0.198–0.320 <0.0001
Comorbid cancer 0.1026 0.040–0.166 0.0014
Comorbid cardiovascular disease -0.0552 -0.016 to -0.094 0.0057
Number of secondary diagnoses 0.0324 0.027–0.038 <0.0001
Respiratory failure 0.0679 0.017–0.118 0.0085
Pleural effusion and empyema 0.2117 0.146–0.278 <0.0001
Abscess 0.5152 0.326–0.705 <0.0001
Congestive heart failure 0.0845 0.045–0.124 <0.0001
APR-DRG severity 0.0721 0.037–0.107 0.0001
Intubation 0.6014 0.432–0.770 <0.0001
Hospital factors
Nonteaching hospital 0.0583 0.014–0.102 0.0095
Northeast region 0.1537 0.077 <0.0001
Admission in 2004 0.0852 0.032–0.138 0.0016
Admission in 2005 0.0534 0.015–0.092 0.0068
Payor factors
Medicare -0.1456 -0.050 to -0.242 0.0029
Other -0.2277 -0.093 to -0.362 0.0009
Overall model:Adjusted r2 = 0.24; chi-square test for model P < 0.0001.
APR-DRG,All Patient Reﬁned Diagnostic-Related Groups; CI, conﬁdence interval; ICD-9, International Classiﬁcation of Diseases, Ninth Revision.
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suggested that up to 85% of the bias resulting from unequal
distributions in patient characteristics can be neutralized by
matching patients by using propensity scores [23]. Multiple
methods have been developed for conducting propensity match-
ing, including stratiﬁed matching, nearest-neighbor matching,
radius matching, kernel matching, and Mahalanobis matching
[23–26]. When there is considerable overlap in the estimated
propensity score between groups, as is the case in the present
study, each matching method should provide similar estimated
treatment effects [26]. After propensity score matching, the
moxiﬂoxacin and levoﬂoxacin cohorts were well balanced, with
no signiﬁcant differences between groups in admission demo-
graphic, clinical, hospital, or payor characteristics. This supports
the conclusion that hospital LOS and charges for inpatient CAP
management do not differ signiﬁcantly between the IV moxi-
ﬂoxacin and levoﬂoxacin regimens studied. Furthermore, multi-
variate analyses of the total cohort showed that the choice of
treatment (moxiﬂoxacin or levoﬂoxacin) was not a signiﬁcant
factor in predicting the hospital LOS or total charges.
The mean LOS of 5.51 to 5.63 days in the propensity-
matched cohorts in this study is similar to mean values of 5.52
days reported in the 2005 Nationwide Inpatient Sample (NIS)
and 5.27 days reported in the 2005 National Hospital Discharge
Survey (NHDS) [5]. The NIS data were drawn from hospitals in
37 states that represented 78% of US community hospitals,
whereas the NHDS data covered all hospitals across the 50
states. The NIS and NHDS data included all patients, whereas
the present study evaluated only those 18 years of age.
Our ﬁndings differed somewhat from those of a similar data-
base analysis conducted by Schein and colleagues, who retrospec-
tively evaluated the PCD database to compare moxiﬂoxacin and
levoﬂoxacin treatment outcomes in patients with CAP from
January 2004 to December 2005 [19]. Apart from the different
study time period, Schein and colleagues included patients who
were hospitalized for3 days but90 days and who received IV
moxiﬂoxacin or IV levoﬂoxacin through the ﬁrst 3 days of hos-
pitalization. In comparison, the present study did not limit total
LOS and consequently did not exclude patients with LOS of90
days, and patients were eligible for the present analysis if they
started IV moxiﬂoxacin or IV levoﬂoxacin treatment on the day
of admission or the following day and continued the regimen for
3 days. In addition, Schein and colleagues did not exclude
patients with surgical DRGs, which may be expected to con-
found LOS and costs. Patients in our study tended to be older (69
years vs. 64 years) and were more likely to be female (58% vs.
52%), reside in the Northeast (15% vs. 12%), not the South
(49% vs. 58%), and were admitted from the emergency depart-
ment (79% vs. 71%) than those in the Schein et al. analysis.
Mean LOS and total costs in the moxiﬂoxacin and levoﬂoxa-
cin cohorts also differed across the two studies, both before and
after propensity matching. For example, in the propensity-
matched cohorts, Schein and colleagues found the mean LOS to
be 6.37 days with moxiﬂoxacin and 5.83 days with levoﬂoxacin
(P = 0.02) [19], compared to 5.63 days and 5.51 days, respec-
tively, in the present analysis (P = 0.462). Schein and coworkers
also reported total per-patient charges of $7767 with moxiﬂoxa-
cin and $7638 with levoﬂoxacin (P > 0.05), compared to $6624
and $6473 (P = 0.476), respectively, in this study. Given the
considerable overlap in time periods between the two studies,
differences in management practices, such as greater use of short-
course therapy, cannot explain the differences between studies.
Several methodological factors may have contributed to dif-
ferences between the two studies. First, Schein and colleagues
performed propensity matching on approximately 60 variables,
and, after matching, only the number of patients who were
admitted to urban hospitals differed between treatment groups
[19]. Although this appears to be a good match, the mean pro-
pensity score still differed signiﬁcantly between the moxiﬂoxacin
and levoﬂoxacin matched cohorts (P < 0.001) possibly because
an unusually high caliper score of 0.7 was used. The standard
method is to use one quarter of the standard deviation of the
estimated propensity score, so it is unclear why 0.7 was chosen in
their analysis. Second, Schein and colleagues excluded all
patients with LOS of90 days, whereas no LOS limit was placed
on patient inclusion in this analysis. Although the impact of this
exclusion criterion is unknown, it does represent a factor that
would inﬂuence the calculation of LOS and cost. Third, the
multivariate regression analyses performed after propensity
Table 5 Results of generalized linear model analysis of variables associated with total costs
Variable Estimated coefﬁcients Wald 95% CI P-value
Moxiﬂoxacin -0.0155 -0.048 to 0.025 0.532
Demographic factors
Female 0.0611 0.023–0.099 0.0015
Clinical factors
ICD-9 code 482 (other bacterial pneumonia) 0.233 0.156–0.310 <0.0001
Comorbid cancer 0.1831 0.110–0.257 <0.0001
Comorbid COPD 0.1063 0.059–0.154 <0.0001
Number of secondary diagnoses 0.0349 0.029–0.041 <0.0001
Pleural effusion and empyema 0.1942 0.110–0.278 <0.0001
Abscess 0.5179 0.205–0.831 0.0012
Renal failure 0.0648 0.017–0.113 0.0083
Congestive heart failure 0.1571 0.113–0.201 <0.0001
APR-DRG severity 0.0759 0.037–0.115 0.0001
Intubation 0.5931 0.325–0.861 <0.0001
Respiratory therapy 0.1189 0.049–0.189 0.0008
% of LOS spent in ICU 0.5987 0.396–0.802 <0.0001
Hospital factors
Nonteaching hospital 0.0657 0.017–0.114 0.0079
Northeast region 0.1246 0.040–0.210 0.0040
Rural location -0.1063 -0.049 to -0.164 0.0003
Admission in 2004 0.1521 0.094–0.211 <0.0001
Emergency department admission -0.0909 -0.045 to -0.137 0.0001
Overall model:Adjusted r2 = 0.33; chi-square test for model P < 0.0001.
APR-DRG, All Patient Reﬁned Diagnostic-Related Group; CI, conﬁdence interval; COPD, chronic obstructive pulmonary disorder, ICD-9, International Classiﬁcation of Diseases, Ninth Revision;
ICU, intensive care unit; LOS, length of stay.
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matching in the study by Schein and colleagues seemed to include
only a limited number of variables (i.e., urban hospital location,
treatment, and the interaction between urban location and treat-
ment). Urban location was included as an independent variable
because it remained signiﬁcantly different between treatment
cohorts after propensity matching. Notably, variables that are
expected to affect LOS and costs and that were statistically
signiﬁcant in our models, such as comorbidities, severity, com-
plications, hospital teaching status, and hospital admission via
the emergency department, were omitted from the regression
models used by Schein and colleagues.
Treatment consistency—deﬁned in the present study as the
absence of retreatment with the ﬁrst study drug or switching to
or adding another IV antibiotic—was evaluated as a secondary
outcome in the present study. In the propensity-matched cohort,
treatment consistency was achieved by 82.8% of patients who
received moxiﬂoxacin and 78.0% of those who received levof-
loxacin. Logistic regression analysis also demonstrated that treat-
ment with moxiﬂoxacin signiﬁcantly increased the likelihood of
treatment consistency when compared with levoﬂoxacin.
Potential Study Limitations
The retrospective database design of this study has potential
limitations. First, because patients were not randomly allocated
to treatment, propensity score matching was needed to generate
well-balanced cohorts for comparisons between moxiﬂoxacin
and levoﬂoxacin, based on measured demographic and clinical
characteristics of the patients as well as measured payor and
hospital characteristics. Nevertheless, propensity score matching
can be conducted only, based on observable characteristics
(demographic, clinical, hospital, and payor characteristics) in the
database [27]. Characteristics not captured in the database, such
as physician preference, formulary restriction, causative patho-
gen, and antimicrobial resistance rates, could still be different
between the two cohorts. In addition, as in any other retrospec-
tive administrative claims database analysis, patient-level data
were somewhat limited. Although we feel that our propensity
score matching protocol, including multivariate analysis post
matching, effectively generated two very similar cohorts, our
ﬁndings do not serve as a substitute for randomization of patients
into the two treatment groups in terms of excluding certain forms
of bias (e.g., selection bias, treatment-selection bias/confounding
by indication). As another potential limitation, treatment consis-
tency, as operationally deﬁned for the ﬁrst time in the present
study as the absence of retreatment with the ﬁrst study drug or
switching to or adding another IV antibiotic, needs to be further
evaluated and/or validated in distinct populations.
Conclusions
Inpatient management of CAP using IV moxiﬂoxacin 400 mg or
IV levoﬂoxacin 750 mg daily was associated with similar hospi-
tal LOS and total costs in balanced patient populations in the
present retrospective database analysis. Initial treatment with IV
moxiﬂoxacin signiﬁcantly increased the likelihood of treatment
consistency when compared with initial IV levoﬂoxacin treat-
ment using our study criteria. Both ﬂuoroquinolones are recog-
nized as appropriate options for empiric therapy of CAP in
hospitalized patients. On the basis of the present ﬁndings, there
were no signiﬁcant differences between these ﬂuoroquinolones in
hospital LOS or overall costs for the management of CAP in the
hospital setting.
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